1. Home
  2. SRTA vs CTNM Comparison

SRTA vs CTNM Comparison

Compare SRTA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SRTA

Strata Critical Medical Inc.

HOLD

Current Price

$5.49

Market Cap

530.4M

Sector

N/A

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$13.53

Market Cap

550.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRTA
CTNM
Founded
2014
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
530.4M
550.7M
IPO Year
2019
2024

Fundamental Metrics

Financial Performance
Metric
SRTA
CTNM
Price
$5.49
$13.53
Analyst Decision
Strong Buy
Buy
Analyst Count
4
4
Target Price
$7.81
$19.00
AVG Volume (30 Days)
680.8K
431.9K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
242.86
0.46
EPS
N/A
N/A
Revenue
$197,141,000.00
N/A
Revenue This Year
$39.27
N/A
Revenue Next Year
$8.52
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.95
$8.60
52 Week High
$6.50
$17.79

Technical Indicators

Market Signals
Indicator
SRTA
CTNM
Relative Strength Index (RSI) 46.16 38.32
Support Level $5.35 $13.65
Resistance Level $5.48 $15.36
Average True Range (ATR) 0.18 0.86
MACD -0.00 -0.30
Stochastic Oscillator 58.89 17.66

Price Performance

Historical Comparison
SRTA
CTNM

About SRTA Strata Critical Medical Inc.

Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: